Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.

The prevalence of carbapenemase-producing Enterobacterales (CPE) is increasing globally, with a marked trend for MBL-producing isolates—this pandemic shows large geographical disparities, with a North/South gradient and higher prevalence in low- and middle-income countries (Table 2 ) [ 8 , 20 – 23 ].

also in 162 other papers